Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01766336 · ClinicalTrials.gov registry record · Phase 2
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Phase 2 study, sponsored by OPKO Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 296
- Enrollment target
NCT01766336 is a Phase 2 study that was terminated before completion, run by OPKO Health. The registered enrollment target is 296 participants.
The verdict
NCT01766336, a Phase 2 study, was terminated before completion, sponsored by OPKO Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 296 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of ELND005 treatment with up to 36 weeks exposure, in Moderate to Severe AD patients with agitation and aggression.
Interventions
- DRUG Group 1 ELND005
- DRUG Group 2 ELND005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 296 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01766336
The ClinicalTrials.gov registry entry for NCT01766336 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 296 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OPKO Health, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Group 1 ELND005 is the first listed.
NCT01766336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01766336 about?
NCT01766336 is a clinical study titled "A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease". To evaluate the safety and tolerability of ELND005 treatment with up to 36 weeks exposure, in Moderate to Severe AD patients with agitation and aggression.
What is the current status of trial NCT01766336?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 296 participants. The study started on 2013-01. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01766336?
The interventions under investigation include: Group 1 ELND005 (DRUG), Group 2 ELND005 (DRUG).
Who is sponsoring clinical trial NCT01766336?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.